Morgan Stanley upgraded Steris (STE) to Overweight from Equal Weight with a price target of $276, up from $260. The firm’s work on the potential margin gains from the shift to E-Beam, consolidation of volumes and pricing power on NESHAP compliance costs, improving bioprocessing trends, and potential tailwind from Olympus’ import ban into the U.S., all leave the firm more positive on Steris, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STE: